Drug profile

The FDA adverse-event record for Flumethrin-Imidacloprid

975 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Flumethrin-Imidacloprid. See the species affected, top reactions, and outcomes below.

975
adverse-event reports
4.1%
death-coded share
Dog
most-reported species
341
Lack of efficacy (ectoparasite) - flea - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
975
Total Reports
40
Deaths Reported
4.1%
Death Rate

Active Ingredients

Flumethrin-Imidacloprid

Administration Routes

TopicalUnknownOralOther

Species Affected

Dog 613
Cat 361
Human 1

Most Affected Breeds

Domestic Shorthair 219
Retriever - Labrador 51
Domestic Longhair 48
Crossbred Canine/dog 40
Cat (unknown) 38
Terrier - Yorkshire 36
Dog (unknown) 35
Chihuahua 35
Shepherd Dog - German 32
Domestic Mediumhair 26

Most Reported Reactions

Lack of efficacy (ectoparasite) - flea 341
Pruritus 261
Lethargy (see also Central nervous system depression in 'Neurological') 132
Application site pruritus 122
Application site alopecia 119
Application site erythema 90
Behavioural disorder NOS 86
Anorexia 63
Vomiting 59
Application site lesion 55
Application site scab 49
Skin lesion NOS 46

Outcome Breakdown

Outcome Unknown
651 (66.8%)
Recovered/Normal
278 (28.5%)
Died
21 (2.2%)
Euthanized
19 (1.9%)
Ongoing
5 (0.5%)
Recovered with Sequela
1 (0.1%)

Flumethrin-Imidacloprid Adverse Event Insights

975 reports name Flumethrin-Imidacloprid; 40 recorded a death outcome (4.1% of reported events, not a population-level mortality rate). Active ingredient: Flumethrin-Imidacloprid. Administration routes: Topical, Unknown, Oral, Other.

By species: Dog (613 reports), Cat (361 reports), Human (1 reports). By breed: Domestic Shorthair (219), Retriever - Labrador (51), Domestic Longhair (48).

Leading clinical signs: Lack of efficacy (ectoparasite) - flea (341), Pruritus (261), Lethargy (see also Central nervous system depression in 'Neurological') (132), Application site pruritus (122). Outcome, 975 coded reports: Outcome Unknown leads at 66.8%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.